Peter Yunker boils down his advice for researchers wanting to commercialize their lab advances. 

“You can’t go it alone,” said Yunker, an associate professor of physics at Georgia Tech. 

In January, Yunker co-founded the biotechnology startup TopoDx LLC, with David Weiss, an Emory University School of Medicine researcher and director of the Emory Antibiotic Resistance Center, and Yogi Patel, a Georgia Tech alumnus with a background in business development and bioengineering. 

“Researchers often think that they have a good commercialization idea to help people, but that alone does not guarantee success,” said Yunker. “Look for partners with complementary skills who understand aspects of the commercialization process that you don’t. Find mentors with business and scientific backgrounds in the specific industry you want to enter.”

TopoDx has developed a microbial test to identify antibiotic resistance and susceptibility rapidly and accurately. Current tests produce a result in three to five days. TopoDx’s approach can gain a result within four hours. Every hour counts in treating serious infections. Delays in accurate treatment can increase antibiotic resistance, which is a global challenge, causing up to 1 million deaths a year. 

The company’s testing method was inspired by a fundamental biophysics project in Yunker’s lab. His team was interested in understanding how bacterial colonies behave. They tested white-light interferometry, a technology that can measure bacterial colonies down to the nanometer level. 

“White-light interferometry allowed us to identify changes in the topography of a colony that indicated larger changes in the volume of cells in the entire colony,” said Yunker. “We thought this might have practical applications.” 

The next step was giving research talks at meetings and looking for collaborators. “I wanted to find someone with expertise on the bacteriology side, and I was very fortunate to meet David Weiss,” Yunker said, noting his proficiency in heteroresistance, a phenomenon where a small subset of a bacterial colony resists an antibiotic. 

“If you have just one antibiotic-resistant cell in a hundred cells, it can cause treatments to fail,” said Yunker. 

The two collaborators hoped to commercialize their technology, identifying heteroresistance in microbial samples. However, they needed guidance in creating a business model. They consulted Harold Solomon, an entrepreneur with Georgia Tech VentureLab and a principal in the Quadrant-i program, a specialized program helping Georgia Tech faculty and students commercialize research.  

Solomon became a key mentor. He guided them away from an ill-advised partnership and instead introduced them to Yogi Patel, who became a co-founder and the company CEO. 

This new collaboration provided the team with an important lesson — one that Yunker passes along to other researchers looking to commercialize their discoveries. “Seek expertise outside your field, be humble about your knowledge limitations, and view collaboration as a strategic partnership,” he says.

When Patel came on board, he conducted extensive interviews with more than 15 clinical professionals.

“You need to interview end users or purchasers of whatever solution you want to build,” said Patel. “Ask them if the problem you think you may have solved is a problem with scale, with a market need.” 

Clinicians, Patel learned, did not see heteroresistance as a significant issue. Instead, the slow pace of antibiotic testing was identified as a major problem. Faster testing could allow clinicians to prescribe targeted drugs more quickly and accurately, reducing unnecessary antibiotic use and the risk of multi-resistant infections. 

With this survey information, Patel asked Yunker and Weiss to rethink how their technology could be commercialized. 

“A company must solve a real-world problem,” said Patel. “I recommended that we switch from heteroresistance to solving slow antibiotic testing. We could keep heteroresistance as something we can still do as a second or third priority.” 

TopoDx’s new technology can measure, with single-nanometer accuracy, how bacterial colonies are responding to antibiotics in real time. This method could revolutionize how antibiotics are tested and prescribed. Testing would be conducted on a countertop device about the size of a large microwave. The co-founders envision the device as eventually being used by urgent care facilities and hospitals. 

“We want to make microbial testing susceptibility accessible anywhere and everywhere,” said Patel.   

Adam Krueger, once a Ph.D. student in Yunker's lab, has continued to refine the technology. Now a post-doctoral researcher, Krueger joined TopoDx in a technical leadership role to expand the technology’s capabilities for microbiological diagnostics.

“We will keep pushing the envelope forward scientifically while we try to commercialize the accomplishments that we have already made,” Yunker said. “We hope that some fundamental studies we are doing now out of scientific curiosity could lead to further commercial applications.”

Georgia Tech faculty members and graduate students, join the Quadrant-i Startup Launch Program to commercialize your research this summer: Over 12 weeks, you'll receive comprehensive support including guidance from experienced mentors, a $10,000 commercialization grant, and $150,000 worth of in-kind services. Showcase your innovation at Demo Day, where you'll have the opportunity to present to over 1,500 attendees, including industry leaders and investors. Apply today! Applications close April 11.